Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM73C4K)

Drug Name
Cryptophycin Drug Info
Synonyms
Cryptophycin 1; cryptophycin; UNII-XO974V2M5T; 124689-65-2; XO974V2M5T; 10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone; CRYPTOPHYCIN A; 1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-((3-chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-; C35H43ClN2O8; AC1O5PMQ; CHEMBL441018; SCHEMBL1346966; PSNOPSMXOBPNNV-VVCTWANISA-N; LS-172597; C16877
Cross-matching ID
PubChem CID
6438401
CAS Number
CAS 124689-65-2
TTD Drug ID
DM73C4K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tubulin (TUB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [2]
Vinorelbine DMVXFYE Advanced cancer 2A00-2F9Z Approved [3]
Cabazitaxel DMPAZHC Breast cancer 2C60-2C65 Approved [4]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [5]
Ixabepilone DM2OZ3G Breast cancer 2C60-2C65 Approved [4]
Eribulin DM1DX4Q Breast cancer 2C60-2C65 Approved [4]
Epothilon DMITJRU Ovarian cancer 2C73 Phase 3 [6]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
BMS-188797 DML1CK2 Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
Indibulin DM6OFJ8 Advanced sarcoma 2A60-2C35 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inducer [1]

References

1 Single-walled tubulin ring polymers. Biopolymers. 2007 Aug 5-15;86(5-6):424-36.
2 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
3 Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
6 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
7 Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
8 Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
9 2011 Pipeline of ZioPharm.